Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Ting Ying Ng"'
Autor:
Jennifer K. Y. Ko, Charleen S. Y. Cheung, Heidi H. Y. Cheng, Sofie S. F. Yung, Ting Ying Ng, Winnie W. Y. Tin, Ho Yan Yuen, Martin H. C. Lam, Ann S. Y. Chan, Sara W. W. Fung, Vivian C. M. Man, Ava Kwong, Ernest H. Y. Ng
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Breast cancer is the most common cancer in reproductive age women. The aim of this study is to assess the knowledge, attitude and intention on fertility preservation among women diagnosed to have breast cancer. This is a multi-centre cross-s
Externí odkaz:
https://doaj.org/article/6026e0d5f812439786e925b7ba7b320e
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
Abstract Background Prognoses of most adult Hodgkin lymphoma (HL) patients are excellent; most of them can achieve permanent remission that can be considered cured. However, many are under-treated or over-treated by standard modern therapies. An accu
Externí odkaz:
https://doaj.org/article/d50b16606c6e490c831d0a7b760f8119
Autor:
Masakazu Toi, Zhimin Shao, Sara Hurvitz, Ling-Ming Tseng, Qingyuan Zhang, Kunwei Shen, Donggeng Liu, Jifeng Feng, Binghe Xu, Xiaojia Wang, Keun Seok Lee, Ting Ying Ng, Antonia Ridolfi, Florence Noel-baron, Francois Ringeisen, Zefei Jiang
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-13 (2017)
Abstract Background The current exploratory analysis was performed to evaluate the efficacy and safety of everolimus for treatment of human epidermal growth factor receptor 2-positive (HER2+) advanced breast cancer in the Asian subset of patients in
Externí odkaz:
https://doaj.org/article/3f86af985baa4e6283f302dee1bbb3e7
Publikováno v:
Leukemia Research Reports, Vol 7, Iss C, Pp 23-28 (2017)
Multiple myeloma is a relatively uncommon plasma cell malignancy. Preclinical and clinical studies have suggested that aspirin might modify the risk of multiple myeloma. We performed a systematic review and meta-analysis of studies to examine the ass
Externí odkaz:
https://doaj.org/article/baec08b41fb94226b02b4913ccddd271
Autor:
Chiun-Sheng Huang, Guofang Sun, Ling-Ming Tseng, Yi Feng, Kunwei Shen, Youngsen Yang, Ava Kwong, Shusen Wang, Mei-Ching Liu, Ting-Ying Ng, Zhimin Shao, Shin-Cheh Chen, Iris Renfei Yan
Publikováno v:
Breast Cancer Research and Treatment. 187:759-768
In the KATHERINE study (NCT01772472), patients with HER2-positive early breast cancer (EBC) and residual invasive disease after neoadjuvant chemotherapy plus HER2-targeted therapy who were treated with adjuvant trastuzumab emtansine (T-DM1) had a 50%
Autor:
Ting Ying Ng, Sarah Park, Tae You Kim, Moon Hee Lee, Joanne Chiu, Gyungyub Gong, Christos Nathaniel, Janice Tsang, Kyong Hwa Park, In Gu Do, Young Jin Choi, Yoon Sim Yap, Jungsil Ro, Joohyuk Sohn, Sung Bae Kim, Gerardo H. Cornelio, Soonmyung Paik, Suee Lee, Ho Suk Oh, Eun Mi Lee
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose BioPATH is a non-interventional study evaluating the relationship of molecular biomarkers (PTEN deletion/downregulation, PIK3CA mutation, truncated HER2 receptor [p95HER2], and tumor HER2 mRNA levels) to treatment responses in Asian patients
Autor:
Ming-Shen Dai, Yin Hsun Feng, Shang Wen Chen, Norikazu Masuda, Chung Cheung Thomas Yau, Shou Tung Chen, Yen Shen Lu, Yoon Sim Yap, Peter Cher Siang Ang, Sung Chao Chu, Ava Kwong, Keun Seok Lee, Samuel Ow, Sung Bae Kim, Johnson Lin, Hyun Cheol Chung, Roger Ngan, Victor C. Kok, Kun Ming Rau, Takafumi Sangai, Ting Ying Ng, Ling Ming Tseng, Richard Bryce, Kiana Keyvanjah, Judith Bebchuk, Mei Chieh Chen, Ming-Feng Hou
Purpose: Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, has demonstrated systemic efficacy and intracranial activity in various stages of HER2+ breast cancer. NALA was a phase III randomized trial that assessed the efficacy and safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::981e0a30098eb7c9a7ed1bc47ef2cf3d
https://doi.org/10.21203/rs.3.rs-404446/v1
https://doi.org/10.21203/rs.3.rs-404446/v1
Autor:
Takafumi Sangai, Thomas Yau, Yen-Shen Lu, Kun Ming Rau, Ting Ying Ng, Ming-Shen Dai, Roger K.C. Ngan, Johnson Lin, Ming-Feng Hou, Sung-Bae Kim, Peter Ang, Ava Kwong, Mei Chieh Chen, Shang Wen Chen, Norikazu Masuda, Richard A. Bryce, Sung Chao Chu, Hyun Cheol Chung, Samuel Ow, Judith Bebchuk, Yin Hsun Feng, Yoon Sim Yap, Keun Seok Lee, Ling Ming Tseng, Victor C. Kok, Shou Tung Chen
Publikováno v:
Breast Cancer Research and Treatment
Purpose Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, has demonstrated systemic efficacy and intracranial activity in various stages of HER2+breast cancer. NALA was a phase III randomized trial that assessed the efficacy and safety of
Publikováno v:
Leukemia Research Reports
Leukemia Research Reports, Vol 7, Iss C, Pp 23-28 (2017)
Leukemia Research Reports, Vol 7, Iss C, Pp 23-28 (2017)
Multiple myeloma is a relatively uncommon plasma cell malignancy. Preclinical and clinical studies have suggested that aspirin might modify the risk of multiple myeloma. We performed a systematic review and meta-analysis of studies to examine the ass
Publikováno v:
American journal of clinical oncology. 42(2)
Objectives Previous studies reported that prognostic nutritional index (PNI), a marker of host inflammatory and nutritional status, is associated with prognoses in a number of cancer types. Thus, we investigated PNI at diagnosis as a prognostic facto